Friday, February 10, 2012

FDA Panel Votes to Restrict Avandia

(Reuters) UPDATED 2010-07-14
An advisory panel reporting to the U.S. Food and Drug Administration (FDA) is recommending that the diabetes drug Avandia be kept on the market, with major restrictions. This decision comes after a two-day meeting in which 33 health experts heard evidence on whether Avandia increases the risk of patient heart attacks and death. Drugmaker GlaxoSmithKline was faulted by some panel members for falsifying data on major side effects, and in the end 17 of the panel members voted to keep the drug on the market, with restrictions. Twelve panel members voted for withdrawal of the medication, and 3 for no change at all. Experts point out that the FDA is not required to follow the recommendation of the advisory panel, though they usually do.

  Read full story >
See all Diabetes News

People who read this also read...